Akebia Therapeutics (AKBA) closed at $0.45 on November 16, 2026, down 5.4% from the previous close, on volume of 3,737,542 shares (30-day average 8,469,958).
Data as of November 16, 2026.
Akebia lands up to $140M loan facility; clears $55M BlackRock debt
Seeking Alpha News (Mon, 16-Nov 8:37 AM ET)
Akebia Therapeutics Enters New Senior Secured Term Loan Facility
TipRanks (Mon, 16-Nov 8:31 AM ET)
Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
Globe Newswire (Mon, 16-Nov 8:00 AM ET)
Akebia Earnings Call Signals Vafseo Growth Amid Revenue Strain
TipRanks (Sat, 14-Nov 10:48 PM ET)
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Globe Newswire (Thu, 5-Nov 7:10 AM ET)
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Globe Newswire (Thu, 29-Oct 8:00 AM ET)
Globe Newswire (Mon, 26-Oct 9:20 AM ET)
Globe Newswire (Wed, 7-Oct 8:00 AM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Akebia Therapeutics trades on the NASDAQ stock market under the symbol AKBA.
As of November 17, 2026, AKBA stock price declined to $0.40 with 2,637,773 million shares trading.
AKBA has a beta of 1.29, meaning it tends to be more sensitive to market movements. AKBA has a correlation of 0.03 to the broad based SPY ETF.
AKBA has a market cap of $111.07 million. This is considered a Micro Cap stock.
Last quarter Akebia Therapeutics reported $37 million in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-10 million and missed earnings estimates by -$.02.
In the last 3 years, AKBA traded as high as $4.08 and as low as $.36.
The top ETF exchange traded funds that AKBA belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWO.
AKBA has underperformed the market in the last year with a price return of -76.0% while the SPY ETF gained +9.6%. AKBA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -54.2% and -43.5%, respectively, while the SPY returned -5.9% and -3.1%, respectively.
AKBA support price is $.42 and resistance is $.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA shares will trade within this expected range on the day.